Ka hopena lōʻihi o COVID-19

Hōʻike pinepine ka poʻe i pili i ka luhi a me ka ʻeha kino.Nui ka poʻe e nalowale ko lākou ʻono a honi paha, lohi ko lākou lolo a ʻaʻole hiki iā lākou ke noʻonoʻo, ʻo ia ka pilikia maʻamau.Ke hopohopo nei ka poʻe loea i hiki ʻole ke ola hou kekahi mau maʻi me nā sequelae lōʻihi o COVID-19.

I kēia manawa, ʻoi aku ka nui o nā sequelae lōʻihi o COVID-19 i ka maka.I Pepeluali, ua hoʻolaha ka NATIONAL Institutes of Health i kahi $ 1.15 biliona hoʻolālā e hoʻoholo ai i nā kumu o ka sequelae lōʻihi o COVID-19 a loaʻa i nā ala e pale ai a mālama i ka maʻi.

Ma ka hopena o Iune, ua ʻoi aku ma mua o 180 miliona mau kānaka i hoʻāʻo maikaʻi no SARS-CoV-2, a he mau haneli miliona hou aʻe e loaʻa i ka maʻi me SARS-CoV-2, me nā lāʻau lapaʻau hou e hoʻomohala ʻia e hoʻoponopono i kahi helu nui. hiki i nā hōʻailona hou i ka lāʻau lapaʻau.

Ke alakaʻi nei ʻo PureTech Health i kahi hoʻāʻo hoʻokolohua maʻi II o ka ʻano deuterated o pirfenidone, LYT-100.Ua ʻae ʻia ʻo Pirfenidone no ka idiopathic pulmonary fibrosis.Hoʻokumu ʻo Lyt-100 i nā cytokine pro-inflammatory, me IL-6 a me TNF-α, a hoʻemi i ka hōʻailona TGF-β e pale i ka hoʻopaʻa ʻana o ka collagen a me ka hoʻokumu ʻana i ka scar.

Ke hoʻāʻo nei ʻo CytoDyn i kāna CC motactic chemokine receptor 5 (CCR5) antagonist leronlimab, he kanaka IgG4 monoclonal antibody, ma kahi hoʻāʻo 2 o 50 poʻe.Hoʻokomo ʻia ʻo CCR5 i nā kaʻina hana maʻi, me ka maʻi HIV, ka sclerosis lehulehu, a me ka maʻi maʻi metastatic.Ua hoʻāʻo ʻia ʻo Leronlimab i nā hoʻokolohua lapaʻau 2B / 3 ma ke ʻano he lapaʻau hou no ka maʻi hanu i nā maʻi maʻi maʻi me COVID-19.Hōʻike nā hopena e loaʻa i ka lāʻau ka pōmaikaʻi ola ke hoʻohālikelike ʻia me nā lāʻau lapaʻau maʻamau, a ʻo ka haʻawina ʻo 2 o kēia manawa e noiʻi i ka lāʻau lapaʻau ma ke ʻano he lapaʻau no nā ʻano hōʻailona ākea.

Ua hōʻike ʻo Ampio Pharmaceuticals i nā hopena maikaʻi o ka pae 1 no kāna cyclopeptide LMWF5A (aspartic alanyl diketopiperazine), ka mea e mālama ai i ka ʻeha nui i loko o ka māmā, a ʻōlelo ʻo Ampio ua hoʻonui ka peptide i nā kumu make āpau i nā maʻi me ka ʻeha hanu.I ka hoʻāʻo hou ʻana o ka Phase 1, ʻo nā mea maʻi me nā hōʻailona hanu e mau ana i ʻehā mau pule a ʻoi aʻe paha e mālama pono ʻia ma ka home me ka nebulizer no nā lā ʻelima.

Ua hoʻohana ʻo Synairgen ma United Kingdom i kahi ala like e hoʻohui i nā sequelae COVID-19 lōʻihi i kahi hoʻokolohua lapaʻau 3 o SNG001 (inhaled IFN-β).Ua hōʻike ʻia nā hualoaʻa mai kahi haʻawina ʻāpana 2 o ka lāʻau lapaʻau i ka maikaʻi o SNG001 i ka hoʻomaikaʻi ʻana o ka maʻi, hoʻihoʻi hou, a me ka hoʻokuʻu ʻana i hoʻohālikelike ʻia me kahi placebo i ka lā 28.